Faricimab▼ in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials
This presentation reports the year 1 primary results from the TENAYA and LUCERNE phase 3 pivotal trials of faricimab▼, a bispecific Ang-2/VEGF-A inhibitor,, in patients with neovascular age-related macular degeneration. TENAYA and LUCERNE investigated the efficacy, safety, and durability of faricimab▼, administered at individualized treatment intervals of up to every 16 weeks, compared with aflibercept administered every 8 weeks.